Cardiol Therapeutics Inc Class A (TO:CRDL) — Market Cap & Net Worth
Market Cap & Net Worth: Cardiol Therapeutics Inc Class A (CRDL)
Cardiol Therapeutics Inc Class A (TO:CRDL) has a market capitalization of $201.02 Million (CA$277.89 Million) as of September 17, 2026. Listed on the TO stock exchange, this Canada-based company holds position #16606 globally and #509 in its home market, demonstrating a -15.41% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cardiol Therapeutics Inc Class A's stock price CA$2.58 by its total outstanding shares 111680087 (111.68 Million). Also see CRDL total assets for a full breakdown of the balance sheet.
Cardiol Therapeutics Inc Class A Market Cap History: 2018 to 2026
Cardiol Therapeutics Inc Class A's market capitalization history from 2018 to 2026. Data shows change from $359.51 Million to $208.43 Million (-5.95% CAGR). Also see Cardiol Therapeutics Inc Class A cash flow conversion for how efficiently the company converts equity into cash flow.
Cardiol Therapeutics Inc Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cardiol Therapeutics Inc Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Cardiol Therapeutics Inc Class A for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2389.99x
Cardiol Therapeutics Inc Class A's market cap is 2389.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $224.59 Million | $78.76K | -$20.65 Million | 2851.57x | N/A |
| 2021 | $188.24 Million | $78.76K | -$24.72 Million | 2389.99x | N/A |
Competitor Companies of CRDL by Market Capitalization
Companies near Cardiol Therapeutics Inc Class A in the global market cap rankings as of September 17, 2026. Review Cardiol Therapeutics Inc Class A tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cardiol Therapeutics Inc Class A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Cardiol Therapeutics Inc Class A Historical Marketcap From 2018 to 2026
Between 2018 and today, Cardiol Therapeutics Inc Class A's market cap moved from $359.51 Million to $ 208.43 Million, with a yearly change of -5.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$208.43 Million | +96.95% |
| 2025 | CA$105.83 Million | -29.19% |
| 2024 | CA$149.46 Million | +68.18% |
| 2023 | CA$88.87 Million | +59.42% |
| 2022 | CA$55.74 Million | -70.39% |
| 2021 | CA$188.24 Million | -16.19% |
| 2020 | CA$224.59 Million | -39.30% |
| 2019 | CA$370.01 Million | +2.92% |
| 2018 | CA$359.51 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Cardiol Therapeutics Inc Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $201.02 Million USD |
| MoneyControl | $201.02 Million USD |
| MarketWatch | $201.02 Million USD |
| marketcap.company | $201.02 Million USD |
| Reuters | $201.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for… Read more